P3MA: A Promising Mycobacteriophage Infecting <i>Mycobacterium abscessus</i>

• Published in: Antibiotics
• Main Authors: Antonio Broncano-Lavado, John Jairo Aguilera-Correa, Françoise Roquet-Banères, Laurent Kremer, Aránzazu Mediero, Mateo Seoane-Blanco, Mark J. van Raaij, Israel Pagán, Jaime Esteban, Meritxell García-Quintanilla
• Format: Article
• Language: English
• Published: MDPI AG 2025-08-01
• Subjects: phage therapy; mycobacteriophage; <i>Mycobacterium abscessus</i>; biofilm; granuloma; antibiotic
• Online Access: https://www.mdpi.com/2079-6382/14/8/801

Background/Objectives: <i>Mycobacterium abscessus</i> is an opportunistic pathogen causing infections mainly in patients with immunosuppression and chronic pulmonary pathologies. Extended treatment periods are needed to tackle this pathogen, bacterial eradication is rare, and recurrence can take place with time. New alternative treatments are being investigated, such as bacteriophage therapy. This work describes the characterization of the mycobacteriophage P3MA, showing its ability to infect clinical and standard <i>M. abscessus</i> strains. Methods: Phylogenetic analysis, electron microscopy, growth curves, biofilm assays, checkerboard, and granuloma-like medium studies were performed. Results: P3MA inhibited the growth of clinical samples in both planktonic and biofilm states as well as in a granuloma-like model. The study of the interaction with antibiotics revealed that P3MA exhibited an antagonistic effect combined with clarithromycin, indifference with amikacin, and synergy with imipenem. Conclusions: All these results suggest that, after genetic engineering, P3MA could be a promising candidate for phage therapy in combination with imipenem, including lung infections.